Raloxifene HCl C28H28ClNO4S structure

C28H28ClNO4S structure
Molecular Formula C28H28ClNO4S
Average mass 510.044 Da
Density
Boiling Point
Flash Point
Molar Refractivity
Polarizability
Surface Tension
Molar Volume
  • Experimental Physico-chemical Properties
  • Miscellaneous
    • Safety:

      GHS07 Biosynth Q-201656
      H315; H319; H335 Biosynth Q-201656
      IRRITANT Matrix Scientific 092959
      None LKT Labs
      [R0243]
      P261; P280; P302+P352; P304+P340; P305+P351+P338; P312 Biosynth Q-201656
      Warning Biosynth Q-201656
    • Target Organs:

      Estrogen/Progestogen Receptor antagonist; SERM agonist TargetMol T1549
    • Drug Status:

      approved BIONET-Key Organics KS-1102
    • Compound Source:

      synthetic-LY-156758 Microsource
      [01505622]
    • Bio Activity:

      Endocrinology/ Hormones TargetMol T1549
      Estrogen and Related Receptors Tocris Bioscience 2280
      Estrogen Receptor ;AO;SERM TargetMol T1549
      Estrogen Receptor/ERR MedChem Express HY-13738A
      Nuclear Receptors Tocris Bioscience 2280
      Others MedChem Express HY-13738A
      RaloxifeneHcl(LY156758 Hcl) is a second generation selective estrogen receptor antagonist. MedChem Express
      RaloxifeneHcl(LY156758 Hcl) is a second generation selective estrogen receptor antagonist.; Target: Estrogen receptor; Approved: September 14, 2007; Raloxifene activates TGF beta 3 promoter as a full agonist at nanomolar concentrations, and raloxifene inhibits the estrogen response element-containing vitellogenin promoter expression as a pure estrogen antagonist in transient transfection assays [1]. MedChem Express HY-13738A
      RaloxifeneHcl(LY156758 Hcl) is a second generation selective estrogen receptor antagonist.;Target: Estrogen receptorApproved: September 14, 2007Raloxifene activates TGF beta 3 promoter as a full agonist at nanomolar concentrations, and raloxifene inhibits the estrogen response element-containing vitellogenin promoter expression as a pure estrogen antagonist in transient transfection assays [1]. Raloxifene, has been demonstrated as a potent uncompetitive inhibitor of human liver aldehyde oxidase-catalyzed oxidation of phthalazine, vanillin, and nicotine-Delta1′(5′)-iminium ion, with Ki values of 0.87 nM, 1.2 nM and 1.4 nM. Raloxifene has also been shown to be a noncompetitive inhibitor of an aldehyde oxidase-catalyzed reduction reaction of a hydroxamic acid-containing compound, with a Ki of 51 nM [2]. Raloxifene (3 mg/kg/day) has potent estrogenic activity on bone resorption and serum cholesterol, a lesser effect on bone formation, and minimal activity on uterine wet weight in o MedChem Express HY-13738A
      Selective estrogen receptor modulator (SERM) Tocris Bioscience 2280
      Selective estrogen receptor modulator (SERM) that binds to ER? and ER?, and tissue-dependently activates or blocks estrogen-induced transcription. Acts as an antiestrogen in breast and uterine tissue, but displays estrogen agonist activity in bone. In D12 rat hypothalamic cells, inhibits progesterone receptor induction by estrogen with an IC50 of 1 nM. Tocris Bioscience 2280
      Selective estrogen receptor modulator (SERM) that binds to ER? and ER?, and tissue-dependently activates or blocks estrogen-induced transcription. Acts as an antiestrogen in breast and uterine tissue,
      but displays estrogen agonist activity in bone. In D12 rat hypothalamic cells, inhibits progesterone receptor induction by estrogen with an IC50 of 1 nM. Tocris Bioscience 2280

Predicted data is generated using the ACD/Labs Percepta Platform – PhysChem Module

No predicted properties have been calculated for this compound.

Click to predict properties on the Chemicalize site

x

Hi!
I'm Larry

Hi there, would you like to get such a paper? How about receiving a customized one?

Check it out